Search Results

Khondrion, a clinical stage biopharmaceutical company discovering and developing therapies targeting primary mitochondrial diseases, today provides an update from (A) the 28-day double-blind, randomised, placebo-controlled, three-way cross-over KHENERGYZE Phase IIb study in 27 patients, and (B) the ongoing, open label extension KHENEREXT Phase IIb study (7 patients up to 52 weeks) (both studies jointly the “Phase IIb programme”).

Khondrion announced that the last patient has been dosed with sonlicromanol in the KHENERGYZE Phase IIb clinical study.

Khondrion announces today the grant of key patents in the United States of America, Europe and Hong Kong.

Khondrion today announced results from its KHENERGY study, a Phase II exploratory trial with oral KH176 in the m.3243A>G multisystem mitochondrial MELAS and MIDD syndromes and mixed phenotypes.

The approval of Reata Pharmaceuticals’ Skyclarys for Friedreich’s ataxia highlights progress being made in the treatment of rare mitochondrial diseases.

Khondrion announced the publication of a scientific article reporting on the development and unique mode of action of KH176, a clinical-stage drug candidate for the treatment of mitochondrial diseases.